Immunotherapy

Two new cancer drugs have been approved for use on the NHS in Scotland. Pembrolizumab (Keytruda) was approved for advanced bladder cancer, and Ameluz was approved to treat a type of skin cancer. Gregor McNie, Cancer Research UK’s head of external affairs in Scotland, hailed the move as fantastic news. The Scottish Medicines Consortium (SMC) approved pembrolizumab, a type of immunotherapy, after consideration by its patient and clinician engagement process. It will be available for patients who have already been treated with chemotherapy for urothelial cancer, the most common type of bladder cancer, that is advanced or has spread to other parts of the body.

 

See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2018-02-15-drugs-approved-in-scotland-for-bladder-and-skin-cancers